Intra Cellular Therapies reported $71.87M in Sales Revenues for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acadia Pharmaceuticals ACAD:US USD 130.71M 3.85M
ALKERMES ALKS:US USD 252.36M 23.86M
Biocryst Pharmaceuticals BCRX:US USD 75.83M 10.3M
Biogen BIIB:US USD 2.51B 80.6M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Cytokinetics CYTK:US USD 2.51M 86.45M
Esperion Therapeutics ESPR:US USD 18.98M 139K
Gilead Sciences GILD:US USD 7.39B 347M
Halozyme Therapeutics HALO:US USD 208.98M 56.61M
Intra Cellular Therapies ITCI:US USD 71.87M 16.29M
JAZZ PHA JAZZ:US USD 940.65M 7.77M
Johnson & Johnson JNJ:US USD 23.71B 85M
Marinus Pharmaceuticals MRNS:US USD 2.34M 550K
Nektar Therapeutics NKTR:US USD 23.62M 2.04M
Neurocrine Biosciences NBIX:US USD 387.9M 9.7M
Novartis NVS:US USD 13B 159M
Prothena PRTA:US USD 1.52M 205K
Supernus Pharmaceuticals SUPN:US USD 177.35M 7.3M
United Therapeutics UTHR:US USD 516M 49.1M
Vanda Pharmaceuticals VNDA:US USD 130.64M 1.86M